Nathalie Cartier-Lacave to Humans
This is a "connection" page, showing publications Nathalie Cartier-Lacave has written about Humans.
Connection Strength
0.117
-
Souchet B, Audrain M, Billard JM, Dairou J, Fol R, Orefice NS, Tada S, Gu Y, Dufayet-Chaffaud G, Limanton E, Carreaux F, Bazureau JP, Alves S, Meijer L, Janel N, Braudeau J, Cartier N. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice. Acta Neuropathol Commun. 2019 03 18; 7(1):46.
Score: 0.024
-
Cartier-Lacave N, Ali R, Yl?-Herttuala S, Kato K, Baetschi B, Lovell-Badge R, Naldini L, Thrasher A. Debate on Germline Gene Editing. Hum Gene Ther Methods. 2016 08; 27(4):135-42.
Score: 0.020
-
Burlot MA, Braudeau J, Michaelsen-Preusse K, Potier B, Ayciriex S, Varin J, Gautier B, Djelti F, Audrain M, Dauphinot L, Fernandez-Gomez FJ, Caillierez R, Lapr?vote O, Bi?che I, Auzeil N, Potier MC, Dutar P, Korte M, Bu?e L, Blum D, Cartier N. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Hum Mol Genet. 2015 Nov 01; 24(21):5965-76.
Score: 0.018
-
Cartier N, Aubourg P. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol. 2010 Jul; 20(4):857-62.
Score: 0.013
-
Cartier N, Hacein-Bey-Abina S, Von Kalle C, Bougn?res P, Fischer A, Cavazzana-Calvo M, Aubourg P. [Gene therapy of x-linked adrenoleukodystrophy using hematopoietic stem cells and a lentiviral vector]. Bull Acad Natl Med. 2010 Feb; 194(2):255-64; discussion 264-8.
Score: 0.013
-
Souchet B, Audrain M, Alves S, Fol R, Tada S, Orefice NS, Potier B, Dutar P, Billard JM, Cartier N, Braudeau J. Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia. J Prev Alzheimers Dis. 2022; 9(2):338-347.
Score: 0.007
-
N?brega C, Mendon?a L, Marcelo A, Lamazi?re A, Tom? S, Despres G, Matos CA, Mechmet F, Langui D, den Dunnen W, de Almeida LP, Cartier N, Alves S. Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. Acta Neuropathol. 2019 11; 138(5):837-858.
Score: 0.006
-
Audrain M, Fol R, Dutar P, Potier B, Billard JM, Flament J, Alves S, Burlot MA, Dufayet-Chaffaud G, Bemelmans AP, Valette J, Hantraye P, D?glon N, Cartier N, Braudeau J. Alzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression. Mol Neurodegener. 2016 Jan 12; 11:5.
Score: 0.005
-
Fol R, Braudeau J, Ludewig S, Abel T, Weyer SW, Roederer JP, Brod F, Audrain M, Bemelmans AP, Buchholz CJ, Korte M, Cartier N, M?ller UC. Viral gene transfer of APPsa rescues synaptic failure in an Alzheimer's disease mouse model. Acta Neuropathol. 2016 Feb; 131(2):247-266.
Score: 0.005
-
Zerah M, Piguet F, Colle MA, Raoul S, Deschamps JY, Deniaud J, Gautier B, Toulgoat F, Bieche I, Laurendeau I, Sondhi D, Souweidane MM, Cartier-Lacave N, Moullier P, Crystal RG, Roujeau T, Sevin C, Aubourg P. Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. Hum Gene Ther Clin Dev. 2015 Jun; 26(2):113-24.
Score: 0.005
-
Sevin C, Cartier-Lacave N, Aubourg P. Gene therapy in metachromatic leukodystrophy. Int J Clin Pharmacol Ther. 2009; 47 Suppl 1:S128-31.
Score: 0.003